Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/219051
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Morén Núñez, Constanza | - |
dc.contributor.author | De Souza, Ruth Mary | - |
dc.contributor.author | Giraldo, Darly M. | - |
dc.contributor.author | Uff, Christopher | - |
dc.date.accessioned | 2025-02-20T16:45:05Z | - |
dc.date.available | 2025-02-20T16:45:05Z | - |
dc.date.issued | 2022-08-19 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://hdl.handle.net/2445/219051 | - |
dc.description.abstract | The distinguishing pathogenic features of neurodegenerative diseases include mitochondrial dysfunction and derived reactive oxygen species generation. The neural tissue is highly sensitive to oxidative stress and this is a prominent factor in both chronic and acute neurodegeneration. Based on this, therapeutic strategies using antioxidant molecules towards redox equilibrium have been widely used for the treatment of several brain pathologies. Globally, polyphenols, carotenes and vitamins are among the most typical exogenous antioxidant agents that have been tested in neurodegeneration as adjunctive therapies. However, other types of antioxidants, including hormones, such as the widely used melatonin, are also considered neuroprotective agents and have been used in different neurodegenerative contexts. This review highlights the most relevant mitochondrial antioxidant targets in the main neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and Huntington's disease and also in the less represented amyotrophic lateral sclerosis, as well as traumatic brain injury, while summarizing the latest randomized placebo-controlled trials. | - |
dc.format.extent | 18 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijms23169328 | - |
dc.relation.ispartof | International Journal of Molecular Sciences, 2022, vol. 23, num.16 | - |
dc.relation.uri | https://doi.org/10.3390/ijms23169328 | - |
dc.rights | cc-by (c) Morén, C. et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Infermeria Fonamental i Clínica) | - |
dc.subject.classification | Melatonina | - |
dc.subject.classification | Antioxidants | - |
dc.subject.classification | Malalties neurodegeneratives | - |
dc.subject.other | Melatonin | - |
dc.subject.other | Antioxidants | - |
dc.subject.other | Neurodegenerative Diseases | - |
dc.title | Antioxidant therapeutic strategies in neurodegenerative diseases | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 740644 | - |
dc.date.updated | 2025-02-20T16:45:06Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36012599 | - |
Appears in Collections: | Articles publicats en revistes (Infermeria Fonamental i Clínica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
836164.pdf | 869.73 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License